1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Immune-related Adverse Events: new trials by email Literature Review of Immune-related Adverse Events trials Research Report on Immune-related Adverse Events
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Rituximab, Tocilizumab - Immune-related Adverse Events, Advanced Solid Tumor | Phase 2 | Active not recruiting | Columbia University | 7 | 2020-09-25 | 2026-08-03 |
Rituximab (1) · tocilizumab (1)
United States (1)
Brian Henick, MD (1)